Expression of serum miR-122 in CHB with MAFLD patients and establishment of a risk prediction model

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200063555

Enrollment

Unknown

Registered

2022-09-11

Start date

2022-09-10

Completion date

Unknown

Last updated

2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B,MAFLD

Interventions

CHB Group:-

CHB with MAFLD Group:-

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Inclusion criteria of CHB group ? Age = 18 years ? Met the diagnostic criteria of CHB. (2) Inclusion criteria of CHB combined with mafld group ?Age = 18 years ? Both met the diagnostic criteria of CHB and MAFLD. CHB diagnostic criteria According to the guidelines for the prevention and treatment of chronic hepatitis B (2019 Edition), HBsAg and / or HBV DNA positive for more than 6 months. MAFLD diagnostic criteria It conforms to the introduction of international expert consensus on the new definition of metabolic related fatty liver disease: ultrasound examination indicates the presence of fatty liver and meets one of the following three conditions: 1) overweight / obesity; 2) Type 2 diabetes; 3) Metabolic dysfunction (including 2 or more risk factors of metabolic abnormality, ? waist circumference: male and female = 90 and 80cm respectively; ? blood pressure = 135mmhg or antihypertensive treatment; ? triglyceride = 1.7mmol/l or lipid-lowering treatment; ? high density lipoprotein cholesterol 2mg / L.

Exclusion criteria

Exclusion criteria: (1) Patients with other viral infections such as HAV, HCV, HDV, HEV and HIV (2) Patients with autoimmune liver disease, cholestatic liver disease, Wilson's disease, heavy drinking (male = 30g / day, female = 20g / day), drug-induced liver disease and other liver diseases (3) Use of drugs related to liver steatosis (tamoxifen, corticosteroids, methotrexate, etc.) (4) Patients with malignant tumor and severe cardiovascular and cerebrovascular disease (5) Previous liver surgery and liver transplantation (6) Pregnant and lactating women (7) Incomplete clinical data (8) Those who refuse to sign the informed consent form

Design outcomes

Primary

Measure	Time frame
Prevalence of MAFLD in CHB patients;Serum miR-122 levels in two groups;	—

Secondary

Measure	Time frame
Metabolic indexes of two groups of patients;Virological indexes of two groups of patients;	—

Countries

China

Contacts

Public ContactYing Zhu

The First Affiliated Hospital of Dalian Medical University

zhuyingsh52@126.com18098878999

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 1, 2026